SLC5A2 and atrial fibrillation: While these medications have not been associated with an increased risk of AF as an adverse effect [210], comparative analyses suggest they are less effective than SGLT2 inhibitors in preventing new-onset AF in both the general population and high-risk populations, including older adults, women, and patients with cardiovascular disease or chronic kidney disease [211].